III.J.25. Medical Countermeasures for Botulinum Toxin. Develop medical countermeasures against the biological warfare threat of botulinum toxin. By FY97, transition to advanced development a recombinant vaccine that will protect 80 percent of immunized personnel against an aerosol challenge, provide protection against all serotypes, and induce minimum reactogenecity in immunized soldiers (milestone 1).
Supports: Army Modernization Plan, Medical Annex OProject, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).
|STO Manager:||TSO:||TRADOC POC:|
|Dr. Anna Johnson-Winegar||MAJ Mark Seymour||CPT Ensor|